Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Niagen Bioscience (NAGE) Depreciation & Amortization (CF) (2016 - 2025)

Niagen Bioscience (NAGE) has disclosed Depreciation & Amortization (CF) for 12 consecutive years, with $139000.0 as the latest value for Q4 2025.

  • Quarterly Depreciation & Amortization (CF) fell 7.95% to $139000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $612000.0 through Dec 2025, down 7.69% year-over-year, with the annual reading at $612000.0 for FY2025, 7.69% down from the prior year.
  • Depreciation & Amortization (CF) for Q4 2025 was $139000.0 at Niagen Bioscience, down from $157000.0 in the prior quarter.
  • The five-year high for Depreciation & Amortization (CF) was $235000.0 in Q3 2022, with the low at $139000.0 in Q4 2025.
  • Average Depreciation & Amortization (CF) over 5 years is $195200.0, with a median of $206000.0 recorded in 2021.
  • The sharpest move saw Depreciation & Amortization (CF) grew 13.43% in 2023, then fell 29.61% in 2024.
  • Over 5 years, Depreciation & Amortization (CF) stood at $211000.0 in 2021, then increased by 4.74% to $221000.0 in 2022, then fell by 19.91% to $177000.0 in 2023, then fell by 14.69% to $151000.0 in 2024, then decreased by 7.95% to $139000.0 in 2025.
  • According to Business Quant data, Depreciation & Amortization (CF) over the past three periods came in at $139000.0, $157000.0, and $158000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.